Previous Article | Next Article 
Molecular and Cellular Biology, July 1999, p. 4825-4831, Vol. 19, No. 7
0270-7306/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
p53 Mediates Apoptotic Crisis in Primary
Abelson Virus-Transformed Pre-B Cells
Indira
Unnikrishnan,1
Arash
Radfar,2,3
Jenia
Jenab-Wolcott,2,3 and
Naomi
Rosenberg1,2,3,4,*
Department of
Pathology,1 Immunology
Program,2 M.D./Ph.D.
Program,3 and Department of
Microbiology and Molecular Biology,4 Tufts
University School of Medicine, Boston, Massachusetts 02111
Received 22 December 1998/Returned for modification 1 February
1999/Accepted 22 April 1999
 |
ABSTRACT |
Transformation of pre-B cells by Abelson murine leukemia virus
(Ab-MLV) involves a balance between positive, growth-stimulatory signals from the v-Abl oncoprotein and negative regulatory cues from
cellular genes. This phenomenon is reflected by the clonal selection
that occurs during Ab-MLV-mediated transformation in vivo and in vitro.
About 50% of all Ab-MLV-transformed pre-B cells express mutant forms
of p53 as they emerge from this process, suggesting that this protein
may play an important role in the transformation process. Consistent
with this idea, expression of p19Arf, a protein whose
function depends on the presence of a functional p53, is required for
the apoptotic crisis that characterizes primary Ab-MLV transformants.
To test the role of p53 in pre-B-cell transformation directly, we
examined the response of Trp53
/
mice to
Ab-MLV. The absence of p53 shortens the latency of Abelson disease
induction but does not affect the frequency of cells susceptible to
Ab-MLV-induced transformation. However, primary transformants derived
from the null animals bypass the apoptotic crisis that characterizes
the transition from primary transformant to fully malignant cell line.
These effects do not require p21Cip-1, a major downstream
target of p53; however, consistent with a role of p19Arf,
transformants expressing mutant p53 and abundant p19 retain wild-type
p19 sequences.
 |
INTRODUCTION |
Abelson murine leukemia virus
(Ab-MLV) is a highly oncogenic transforming retrovirus. The activity of
the single protein product of the virus, the v-Abl protein tyrosine
kinase, is required to transform cells in vitro and to induce
pre-B-cell lymphomas in vivo (34, 50). Despite the presence
of a dominantly acting oncogene, Ab-MLV-induced transformation is a
multistep process. Even though tumors arise rapidly in vivo, an early
polyclonal phase is followed by a later mono- or oligoclonal phase
(14, 15). In vitro, primary lymphoid transformants undergo a
period of crisis in which many cells die before permanently
established, highly malignant cell lines arise (30, 35, 47, 51,
52). Because changes in expression or activity of the v-Abl
protein do not occur during this phase (52), the process
appears to be mediated by changes in cellular genes that impact the
transformation process.
One cellular gene involved in Ab-MLV transformation is
Trp53, which encodes the p53 tumor suppressor protein; about
50% of all Ab-MLV-transformed pre-B cells express mutant forms of this molecule (30, 47). p53 responds to cellular insults,
including oncogenic stimuli (20, 27, 41). Activation of p53
can induce G1 arrest by inducing the p21Cip-1
cyclin-dependent kinase inhibitor and other target molecules (5,
8, 10, 11, 16, 55). The protein can also mediate apoptosis,
probably by stimulating certain p53-responsive genes and suppressing
others (1, 13, 22, 36, 37, 40). All of these responses
appear to be important for the tumor suppressor functions of p53
(20, 27, 41).
Activation of p53 following oncogenic stimuli, including those from Myc
and E1A, requires a functional p19Arf protein (9, 29,
56), as does the ability of p53 to mediate senescence and block
immortalization of mouse embryo fibroblasts (MEF) (18, 56).
Abundant expression of p19Arf often precedes the emergence
of Trp53 mutations in Ab-MLV-transformed pre-B cells, and
primary transformed pre-B cells derived from Ink4a/Arf
/
mice do not undergo crisis in
vitro (30), suggesting that oncogenic signals from v-Abl
activate the same pathway during transformation of pre-B cells.
Consistent with this idea, upregulation of p19Arf occurs in
response to signals from c-Myc (56), an obligate downstream
target of v-Abl (38, 54, 57). Thus, the outcome of Ab-MLV
infection may reflect the balance achieved by opposing positive
growth-stimulatory signals and negative apoptotic signals.
The p19Arf-p53 regulatory loop provides an attractive
mechanism by which the crisis characteristic of Ab-MLV-mediated
lymphoid transformation may be induced. This model predicts that p53 is a critical element. To test this hypothesis, we examined the response of pre-B cells from Trp53
/
mice to Ab-MLV.
Our data reveal that the absence of p53 shortens the latent period for
induction of Ab-MLV-mediated lymphoma but does not affect the frequency
of primary Ab-MLV-induced transformation. However, p53 is required for
the crisis that characterizes the pre-B-cell transformation process.
Consistent with the predicted role of p19Arf in this
process, cells expressing mutant forms of p53 and abundant levels of
p19Arf retain the wild-type p19Arf sequence.
These data demonstrate that p53 is an important downstream element
mediating the cellular response to oncogenic signals from the v-Abl
protein and reinforce the role of p19Arf in the process.
 |
MATERIALS AND METHODS |
Cells and mice.
Pre-B-cell lines were routinely maintained
in supplemented RPMI 1640 medium (50 µM 2-mercaptoethanol, 2 mM
L-glutamine, 50 µg of streptomycin per ml, and 50 U of
penicillin per ml) containing 10% heat-inactivated fetal calf serum
(Sigma) at 37°C in a 6% humidified CO2 atmosphere. Bone
marrow transformation assays were performed as described previously by
using the Ab-MLV-P160 strain (12, 35). To derive cell lines,
primary transformants were removed from agar at 10 days postinfection
and plated in 24-well plates in supplemented RPMI 1640 medium
containing 20% fetal calf serum. The cultures were monitored daily for
cell density and viability. When the cells filled the well, half of the
cells were transferred to a new well. This process was continued until
the cells grew to confluence and were >85% viable; then, the cells were transferred to a 35-mm dish and subcultured as before. When the
cultures were consistently greater than 90% viable and could be
routinely subcultured, the cells were considered established. Trp53
/
mice were derived from a BALB/cJ
Trp53+/
breeding pair that had been
backcrossed to BALB/cJ five times and inbred for three generations
(Jackson Laboratories). The mice were bred by brother-sister mating at
the Tufts University School of Medicine animal facility. Genotypes were
assessed by PCR amplification of DNA prepared from tail fragments and a
combination of primers specific for Trp53 and the neomycin
resistance gene present in the targeted allele, as recommended by the
supplier. Animals were injected intravenously via the tail vein with
Ab-MLV-P160 and monitored for disease induction; animals were
sacrificed when evidence of tumors, such as hind limb paralysis,
lymphadenopathy, splenomegaly, cachexia, or general ill health, was
noted. Animals were examined for the characteristic features of Abelson
disease, including tumors affecting the lower spinal column and lymph
nodes and sparing the thymus. The
(p21Cip-1)
/
mice were of a mixed
background (8).
Apoptosis analyses.
For merocyanin 540 (MC540) staining of
apoptotic cells (31), cells were collected and washed twice
in phosphate-buffered saline (PBS) containing 0.1% bovine serum
albumin (BSA) (Sigma). A 1-mg/ml stock of MC540 in 50% ethanol
(Molecular Probes) was added to a final concentration of 0.05 µg/ml
in PBS-0.1% BSA, and the cells were analyzed immediately by flow
cytometry with a FACScan instrument. Apoptotic cells are stained
specifically with MC540 (31). To analyze the integrity of
DNA in dying cells, the cells were washed in PBS and resuspended in DNA
lysis buffer (100 mM Tris [pH 8], 20 mM EDTA, 0.8% sodium lauryl
sarcosinate), and 3.3 mg of RNase per ml was added (21). The
mixture was incubated for 30 min at 37°C, proteinase K was added to a
final concentration of 5 mg/ml, and the samples were incubated for an
additional 2 h at 50°C. The samples were extracted with
phenol-chloroform, precipitated with ethanol, and analyzed by
electrophoresis through 2% agarose gels containing ethidium bromide.
Nucleic acid preparation and sequence analysis.
RNA was
prepared from Ab-MLV-transformed cells by using an RNeasy kit (Qiagen)
according to the manufacturer's instructions. To prepare cDNA, 10 µg
of total RNA was mixed with 1 µM primer, heated to 70°C for 10 min,
and chilled on ice for 5 min. Then, 40 U of RNasin, 5 mM
dithiothreitol, and 25 mM deoxynucleoside triphosphate (dNTP) mix were
added and the mixture was heated at 42°C for 5 min. Synthesis was
conducted for 1 h at 42°C with Moloney murine leukemia virus
reverse transcriptase (GIBCO-BRL). The reaction was stopped by
incubating the samples at 75°C for 10 min. The cDNA was then
amplified by PCR with 250 µM dNTP mix (Pharmacia), 1× PCR buffer
(Perkin-Elmer Cetus), 1 µM (each) primer, and 2.5 U of Taq
polymerase (Perkin-Elmer Cetus). The samples were incubated in a
programmable Thermal Controller (MJ Research) for 34 cycles of 94°C
for 1 min, 57°C for 2 min, and 72°C for 2 min, followed by a 5-min
incubation at 72°C. Control reaction mixtures lacking DNA or from
reverse transcription reactions carried out in the absence of RNA did
not give rise to specific products. Reverse transcription was primed
with the Ink/Arf common antisense primer
5'-GCAAAGCTTGAGGCCGGATTTAGCTCTGCTC-3' (29). To
amplify p16Ink4a cDNA, this primer was used in combination
with the exon 1
primer 5'-CGGGATCCGCTGCAGACAGACTGGCCAG-3'
(29); p19Arf cDNA was amplified with the
common primer and the exon 1
primer 5'-CGCCGCTGAGGGAGTAC-3'.
Ink/Arf locus sequences were amplified from BALB/cByJ
kidney DNA. Exon 1
sequences were amplified with 5'-GTCCAGGATTCCGGTGC-3' and the exon 1
primer used for
cDNA synthesis; exon 2 sequences were amplified with
5'-ACATAGGGCTTCTTTCTTGGGTCC-3' and
5'-GGACCAACTATGCTCACCTGGGC-3'. Each PCR mixture contained 100 to 200 ng of DNA, 125 µM dNTP mix (Pharmacia), 1× PCR buffer (Perkin-Elmer Cetus), 0.5 µM (each) primer, and 1 U of Taq
polymerase (Perkin-Elmer Cetus). The samples were incubated in a
programmable Thermal Controller for 30 cycles of 94°C for 1 min,
55°C for 1.5 min, and 72°C for 1.5 min, followed by a 10-min
incubation at 72°C. All amplified products were cloned into the TA
cloning vector (Invitrogen) and sequenced on an ABI373-stretch machine
(Perkin-Elmer) at the DNA Facility, Department of Physiology, Tufts
University School of Medicine.
Protein analysis.
For Western analysis, cells were washed in
PBS and cell pellets were lysed in a solution of 10 mM Tris (pH 7.4),
1% sodium dodecyl sulfate (SDS), 1 mM phenylmethylsulfonyl fluoride,
and 1 mM sodium orthovanadate (25). The lysates were
heated at 95°C for 5 min and sheared through a 25-gauge needle. The
amount of protein in each lysate was quantified by using a
bicinchoninic acid protein assay kit (Pierce), and 50 µg of each
sample was fractionated through an SDS-polyacrylamide gel. Proteins
were electrotransferred to polyvinylidene difluoride membranes
(Millipore), which were probed with anti-p19Arf
(26) or anti-Gag/v-Abl (H548) (7) antibodies. The
blots were developed with a chemiluminescence kit (Tropix), according to the manufacturer's instructions.
 |
RESULTS |
Absence of Trp53 accelerates Abelson disease in
vivo.
Mutation of Trp53 is a frequent occurrence in
Ab-MLV-transformed pre-B-cell lines (47). To determine if
the presence of a functional p53 affected the induction of Abelson
disease, 5- to 8-week-old Trp53+/+,
Trp53+/
, or Trp53
/
mice were injected with Ab-MLV and monitored for the development of
tumors (Fig. 1). As expected for adult
mice on the highly Ab-MLV-susceptible BALB/c background
(33), all of the injected animals developed tumors.
Irrespective of p53 status, the diseased animals displayed pathological
features characteristic of typical Abelson disease, including hind limb
paralysis, enlarged peripheral lymph nodes, and moderate splenomegaly
with sparing of the thymus (24, 33). However, all of the
null animals developed tumors more rapidly, with a mean latency of 23 days, than did heterozygous or wild-type animals, which displayed mean
latencies of 30 and 31 days, respectively. An even more dramatic shift
in latency has been observed by Zou et al., who have analyzed p53 null,
heterozygous, and wild-type mice on a mixed 129 background
(5a). Thus, the lack of p53 accelerates the development of
Ab-MLV-induced tumors in vivo.

View larger version (14K):
[in this window]
[in a new window]
|
FIG. 1.
Accelerated tumor induction in
Trp53 / mice. Age-matched
Trp53 / ( ),
Trp53+/ ( ), and
Trp53+/+ ( ) mice were injected with
Ab-MLV-P160 and monitored for tumor development. Animals were
sacrificed when tumors were evident; each point represents a single
mouse.
|
|
Absence of p53 does not affect pre-B-cell transformation
frequency.
To determine whether the initiation of Ab-MLV-mediated
transformation is affected by p53 status, bone marrow cells from
Trp53+/+, Trp53+/
, or
Trp53
/
mice were infected with Ab-MLV,
plated in soft agar, and monitored for transformation (35).
All samples gave rise to morphologically typical transformed pre-B-cell
colonies. The colonies obtained from Trp53
/
bone marrow were slightly larger than those found in other samples. Cell counts performed on 10 of these colonies revealed that they contained between 5 × 105 and 1.8 × 106 cells, with an average of 1.1 × 106
cells/colony; 10 colonies from Trp53+/+ mice
contained between 2 × 105 and 1.1 × 106 cells and averaged 6 × 105
cells/colony. The frequency of primary transformants was slightly higher in the samples from Trp53
/
and
Trp53+/
animals in most experiments (Table
1). However, differences in
transformation frequencies of two- to threefold are common when
individual mice from inbred strains are examined (our unpublished data), suggesting that these differences may not reflect the
Trp53 status of the mice. Thus, the initial transformation
frequency by Ab-MLV was not markedly affected by the Trp53
gene. This is consistent with the observation that Trp53
mutations arise late in the transformation process in the Ab-MLV system
(30, 47) and in other types of tumors, including the
BCR/ABL-induced chronic myelogenous leukemia (2, 20, 28,
46).
p53 influences the establishment of primary pre-B-cell
transformants.
Only a fraction of primary pre-B-cell transformants
from normal mice become established cell lines (30, 47, 52).
To determine if p53 affects this parameter, primary transformants from
Trp53+/+, Trp53+/
, and
Trp53
/
mice were removed from agar and
cultured in liquid medium. About 10% of the transformants from
Trp53+/+ mice became established after an
average of 29 days in culture; none were established earlier than 16 days postexplant (Table 2). However, all
87 of the primary transformants isolated from Trp53
/
mice gave rise to established cell
lines 4 to 6 days after explant from agar. Interestingly, primary
transformants from Trp53+/
mice displayed an
intermediate phenotype, with 50% or more of these becoming fully
established in about 2 weeks (Table 2).
Accelerated loss of the single wild-type p53 allele is a common feature
of tumors that arise in
Trp53+/
mice (
3,
4,
17). To determine if similar events might
account for the high
frequency with which the
Trp53+/
cell lines
became established, the presence of wild-type and
targeted alleles in
the cell lines was assessed. PCR analysis
revealed that six of seven
cell lines examined had lost the wild-type
copy of
Trp53
(Fig.
2A). Consistent with these data,
immunoprecipitation
and Western analysis revealed that p53 could not be
detected in
cell lines that lacked a functional
Trp53 allele
(Fig.
2B). Interestingly,
sample 12, from the only cell line that
retained a copy of the
wild-type gene, expressed a p53 protein that
reacted with antibodies
specific for both wild-type and mutant forms of
p53 (Fig.
2B).
Based on analyses of other cell lines (
47),
this pattern likely
reflects the emergence of cells expressing a mutant
form of p53
in this population. These analyses and the high frequency
with
which primary transformants from
Trp53
/
mice become established demonstrate that p53 expression has a
major
effect on the ability of primary transformants to evolve
into
established cell lines.

View larger version (29K):
[in this window]
[in a new window]
|
FIG. 2.
Trp53+/ transformants lose
their remaining Trp53 allele rapidly. (A) DNAs from
representative Trp53+/ transformants were
amplified with primers specific for the wild-type and targeted alleles,
and products were fractionated through an agarose gel containing
ethidium bromide. The numbers above each lane identify the cell clone
from which the sample was derived. DNAs from
Trp53+/ and Trp53+/+
mice and a reaction mix containing no DNA were used as controls. The
unmarked lane contains a 100-bp DNA ladder, used as a marker. Arrows
denote positions of the wild-type (Wt) and mutant (Mut) specific PCR
products. (B) Lysates from the cell lines analyzed in panel A and
control cell lines were immunoprecipitated with anti-p53 antibody Ab-4,
specific for wild-type p53 (lanes W), or anti-p53 antibody Ab-3,
specific for mutant forms of p53, (lanes M) and the immunoprecipitates
were analyzed by Western blotting with anti-p53 antibody Ab-7, which
recognizes both mutant and wild-type p53 forms on Western blots. The
p53 statuses of the control wild-type (204-3-1), mutant (143-2M), and
null (L1-2) cell lines were characterized previously (47).
|
|
p53 is required for induction of the apoptotic crisis.
Primary
Ab-MLV-transformed pre-B cells undergo a crisis marked by apoptotic
cell death several days after they are explanted from agar
(30). To determine if Trp53 plays a role in
crisis induction, the health and viability of primary transformants
derived from Trp53
/
and
Trp53+/+ mice were analyzed. As expected, based
on analysis of primary transformants from many strains of mice, the
Trp53+/+ transformants were highly viable during
the first few days following explant from agar (Fig.
3). However, the viability of most clones decreased by day 5 and often continued to decrease over the next 3 to 4 weeks; a high frequency of these cells underwent apoptosis, as judged
by staining with MC540 (31) and the presence of the DNA
ladder pattern characteristic of programmed cell death (Fig. 4). In contrast to this pattern, the
Trp53
/
transformants displayed viabilities
in excess of 85% throughout the experiment (Fig. 3), and levels of
apoptosis were very low (Fig. 4). These data demonstrate that
expression of a functional p53 is required for induction of the crisis
that characterizes the transformation process.

View larger version (10K):
[in this window]
[in a new window]
|
FIG. 3.
Trp53 is required for crisis induction.
Primary transformants from Trp53+/+ ( ) and
Trp53 / ( ) mice were assessed for
viability by using trypan blue staining when they were removed from
agar cultures and at regular intervals thereafter.
|
|


View larger version (155K):
[in this window]
[in a new window]
|
FIG. 4.
Trp53+/+ transformants undergo
apoptotic crisis during outgrowth. (A) Three independent
Trp53+/+ and Trp53 /
transformants were stained with MC540 (31) and analyzed by
flow cytometry. The percentages of apoptotic cells, represented by
black peaks, are noted. The data shown are representative of analyses
of more than 10 additional independent transformants from each
background. (B) DNA was prepared as described in Materials and Methods
from representative Trp53+/+ and
Trp53 / transformants and fractionated
through an agarose gel containing ethidium bromide. The data shown are
representative of analyses of 10 independent transformants from each
background. Lane M, 100-bp ladder marker.
|
|
p53-dependent crisis occurs in the absence of
p21Cip-1.
One important mediator on the p53 pathway is
the cyclin-dependent kinase inhibitor p21Cip-1 (10,
11, 16, 55). To determine if p21Cip-1 plays a role in
p53-mediated crisis, primary transformants were prepared from the bone
marrow of p21Cip-1
/
mice. These
cells, similar to those from virtually all strains of mice, were highly
viable when explanted from agar. However, like cells from wild-type
mice, all of the primary transformants underwent an apoptotic crisis,
as judged by MC540 staining and DNA laddering analysis (data not
shown), beginning about 5 days after explant and lasting for 30 to 35 days. Many primary transformants succumbed to crisis during this
period, and 39% (18 of 46) became established (Fig.
5). Although the frequency with which
primary transformants from these mice became established was somewhat higher than that observed for Trp53+/+ mice,
these animals are on different genetic backgrounds, making direct
comparisons problematic. The frequencies with which primary transformants become established varies among strains; analyses of
cells from mixed backgrounds similar to that of
p21Cip-1 null mice reveal establishment
frequencies ranging from 20 to 80% (16a). In all of these
instances, the transformation process is accompanied by a profound
apoptotic crisis. Thus, while p21Cip-1 may play some role
in the frequency with which primary transformants become established,
the uniform presence of apoptotic crisis in cells from
p21Cip-1
/
mice demonstrates that
the protein is not required for this phenomenon. Consistent with this
idea, four of eight p21Cip-1
/
transformants tested acquired Trp53 mutations during
expansion (data not shown); this frequency is similar to that observed
with primary transformants from other strains of mice (47).

View larger version (6K):
[in this window]
[in a new window]
|
FIG. 5.
p21Cip-1 /
transformants undergo crisis. Growth and viability of primary
transformants from p21Cip-1 /
mice were monitored as described in Materials and Methods. The times at
which primary transformants succumbed to crisis ( ) and at which cell
lines that survived crisis and became established ( ) are
indicated.
|
|
p19Arf expression is elevated in Trp53 null
transformants.
Our earlier work established a correlation between
expression of Ink4a/Arf locus products and expression of
mutant forms of p53 (30) and suggested that a functional
p19Arf-p53 pathway (27, 41) is required for
crisis. This model predicts that expression of p19Arf is
not deleterious to the growth of transformants from Trp53 null mice. To test this idea, a panel of transformants was examined for
p19Arf expression by Western blotting. All 12 transformants
tested, including the representatives shown (Fig.
6), expressed readily detectable
p19Arf. As shown previously (30), none of the
transformants from control animals expressing wild-type p53 expressed
p19. The sample in lane 9 is representative of a transformant from
wild-type mice that expresses a mutant p53. This pattern of expression
is similar to that observed in other types of cells which lack a
functional p53 protein (18, 29, 45, 56) and is consistent
with the absence of apoptosis following p19Arf
overexpression in transformants lacking a functional p53
(30).

View larger version (20K):
[in this window]
[in a new window]
|
FIG. 6.
p19Arf is expressed in transformants from
Trp53 null mice. Lysates were prepared from transformants
from Trp53 null animals or wild-type (WT) mice and examined
by Western blotting for the presence of the p19Arf protein.
The cells used were derived with either the P120, P90, or P80 strains
of Ab-MLV (24). The transformation properties of these
viruses are similar in wild-type and Trp53 null mice (our
unpublished data). Lysates from NIH 3T3 (p19Arf-negative)
cells and from the p19Arf-positive cell line MEL
(29) were used as controls. The blots were also probed with
the H548 anti-Gag/v-Abl monoclonal antibody (7) to control
for protein loading.
|
|
The hypothesis that p19
Arf functions through p53 in the
Ab-MLV system also predicts that p19
Arf retains functional
potential in cells expressing mutant p53.
To assess the status of p19
in these cells, p19
Arf cDNAs from two independent cell
lines expressing mutant p53 were
amplified, cloned, and sequenced. In
addition, because published
sequence information indicates that
p19
Arf sequences are not identical in all inbred strains
(
23), the
genomic sequences of
Ink4a/Arf exon
1

and exon 2, which encode
the majority of the p19
Arf
protein, were determined by amplifying these regions from BALB/cByJ
liver DNA. Consistent with published information (
23),
comparison
of the BALB/cByJ sequence with that expressed by the MEL
erythroleukemia
cell line from which
p19Arf was
originally cloned (
29) revealed the presence of a sense
variant (T75C) and a missense variant (G257A), resulting in the
substitution of a histidine for an arginine, in BALB/cByJ.
Comparison
of the p19
Arf sequences from both transformants
revealed that they were identical
to the BALB/cByJ sequence obtained
from liver DNA. Similar analyses
revealed that the p16
Ink4a
sequences expressed by these transformants were also identical
to the
published BALB/c sequence. These data suggest that both
Ink/Arf locus products retain their full functional
potential
and support the view that p19
Arf functions
through p53 in Ab-MLV
transformants.
 |
DISCUSSION |
Our results demonstrate that expression of wild-type p53 plays a
key role in the selection process that characterizes the early phases
of Ab-MLV-induced pre-B-cell transformation. The protracted period of
apoptotic crisis that characterizes the transition from primary pre-B
transformant to a fully malignant cell does not occur when primary
transformants are derived from Trp53 null mice. Furthermore,
transformants from heterozygous animals display an intermediate level
of crisis and rapid loss of heterozygosity at Trp53. This
pattern is similar to that obtained in tumors arising in
Trp53+/
mice (3, 4, 17) but
contrasts with the pattern observed in transformants from normal mice
(47, 53). Loss of Trp53 sequence is rare in the
latter circumstance, probably because both copies of Trp53
would have to be altered for the cells to have a selective advantage.
In contrast, a single dominant-negative mutation, such as those found
in Ab-MLV-transformed pre-B cells, is sufficient to ablate protein function.
Despite its dramatic effect on the establishment of primary Ab-MLV
transformants and the slightly higher numbers of B220-positive, immunoglobulin M-negative pre-B cells reported for
Trp53
/
mice (42), the absence of
p53 did not affect the frequency of Ab-MLV-susceptible target cells in
a marked way. BALB/c mice, the strain used here, are highly sensitive
to Ab-MLV transformation in vitro (35), raising the
possibility that effects of p53 on transformation frequency may be less
dramatic in this strain. Enhanced transformation of myeloid progenitors
from Trp53
/
mice on a C57BL/6 background has
been reported (43), and recent work with
Trp53
/
animals on a mixed 129 background
demonstrated higher frequencies of Ab-MLV target cells in null animals
(5a). The absence of p53 also does not affect the phenotype
of the transformants; similar to Ab-MLV transformants from normal mice,
Trp53 null cells express the B220 pre-B-cell differentiation
antigen and have rearranged their immunoglobulin heavy chain genes but
not their light chain genes (our unpublished data).
In contrast to the results obtained in vitro, Trp53 null
animals develop tumors somewhat more rapidly than those which retain a
functional p53 protein. The relatively small differences in the latency
period most likely reflect the high susceptibility of BALB/c mice to
Abelson disease (33). Consistent with this view, a more
dramatic impact on tumor latency was observed when animals on a mixed
129 background were tested (5a). These differences probably
reflect the impact of other genes on Ab-MLV tumorigenesis; two genes
affecting the susceptibility of laboratory mice to Ab-MLV have been
identified, but the mechanisms underlying their effects remain unknown
(32, 33). Consistent with the phenotype of in vitro
transformants, the pattern of tumor development and the morphology of
the tumor cells suggest that tumor cells are similar in the wild-type
and null animals. The differences in latency and the observation that
Abelson disease normally involves clonal selection (14, 15)
suggest that the latter process may be reduced or absent in tumors
arising in Trp53 null animals.
p21Cip-1, an important downstream effector of p53 (10,
11, 16, 55), does not appear to play a major role in
Ab-MLV-induced pre-B-cell transformation. Although we could not compare
the frequencies of target cells in null animals to genetically matched
control animals, comparisons with other mice of similar mixed
background suggest that the null animals have normal numbers of
Ab-MLV-susceptible cells. p21Cip-1 also does not play a
major role in crisis induction, demonstrating that this protein is not
required for the p53-mediated effects on transformation. In addition,
expression of p21Cip-1 induces neither apoptosis nor
obvious changes in cell cycle parameters in Trp53 null
transformants (our unpublished data). These data are consistent with
the fact that p53-mediated apoptosis is p21Cip-1
independent in other types of cells (1, 6, 19, 49).
Primary transformants derived from Trp53
/
mice are strikingly similar to those derived from
Ink4a
/
mice; in both cases, virtually all
primary transformants become established very rapidly and the apoptotic
crisis that characterizes the transformation process does not occur
(30). These data and the correlation between
p19Arf expression and p53 status (30) suggest
that these two proteins function in an interdependent fashion during
transformation. A similar relationship has been observed when MEF
undergo senescence in vitro (18, 56). In this instance, loss
of either p19Arf or p53 permits the emergence of
immortalized cells. However, senescence is a normal cell process
characterized by specific changes in gene expression and cell cycle
arrest (44, 48). Most normal lymphoid cells do not grow
extensively in vitro, even in the presence of lymphokines, and a
process similar to senescence has not been documented in this cell
type. Nonetheless, because expression of some oncogenes induces changes
in MEF that resemble senescence (39), determining if primary
transformants undergoing crisis share features with senescent cells
could help to illuminate the mechanisms involved.
The relationship between p19Arf expression and the
emergence of cells expressing wild-type p53 suggests that the
p19Arf-p53 regulatory loop (27, 41) is an
important cellular response to Ab-MLV pre-B-cell infection. This
response may be triggered by v-Abl-mediated activation of c-Myc, an
important downstream target of v-Abl (38, 54, 57), which in
turn can activate p19Arf (56). Indeed, because
the vast majority of Ab-MLV transformants either express mutant p53 or
fail to express p19Arf once they are fully established
(30), this pathway may serve as the major cellular
gatekeeper modulating Ab-MLV transformation.
 |
ACKNOWLEDGMENTS |
We thank Philip Leder, Ronald DePinho, and Andrew Beavis for
providing reagents critical to this work; Henry Wortis and Allen Parmelee for assistance with flow cytometry; Zohar Sachs for assistance with mice; and Anne Halgren for technical support.
This work was supported by grant CA33771 from the National Institutes
of Health.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: SC315, Tufts
University School of Medicine, 136 Harrison Ave., Boston, MA 02111. Phone: (617) 636-6906. Fax: (617) 636-0337. E-mail:
nrosenbe{at}opal.tufts.edu.
 |
REFERENCES |
| 1.
|
Attardi, L. D.,
S. W. Lowe,
J. Brugarolas, and T. Jacks.
1996.
Transcriptional activation by p53, but not induction of the p21 gene, is essential for oncogene-mediated apoptosis.
EMBO J.
15:3693-3701[Medline].
|
| 2.
|
Baker, S.,
S. Markowitz,
E. Fearson,
J. Wilson, and B. Vogelstein.
1990.
Suppression of human colorectal carcinoma cell growth by wild-type p53.
Science
249:912-914[Abstract/Free Full Text].
|
| 3.
|
Baxter, E. W.,
K. Blyth,
L. A. Donehower,
E. R. Cameron,
D. E. Onions, and J. C. Neil.
1996.
Moloney murine leukemia virus-induced lymphomas in p53-deficient mice: Overlapping pathways in tumor development?
J. Virol.
70:2095-2100[Abstract].
|
| 4.
|
Blyth, K.,
A. Terry,
M. O'Hara,
E. W. Baxter,
M. Campbell,
M. Stewart,
L. A. Donehower,
D. E. Onions,
J. C. Neil, and E. R. Cameron.
1995.
Synergy between a human c-myc transgene and p53 null genotype in murine thymic lymphomas: contrasting effects of homozygous and heterozygous p53 loss.
Oncogene
10:1717-1723[Medline].
|
| 5.
|
Brugarolas, J.,
C. Chandrasekaran,
J. I. Gordon,
D. Beach,
T. Jacks, and G. J. Hannon.
1995.
Radiation-induced cell cycle arrest compromised by p21 deficiency.
Nature (London)
377:552-556[Medline].
|
| 5a.
| Calame, K. Personal communication.
|
| 6.
|
Chen, X.,
L. J. Ko,
L. Jayaraman, and C. Prives.
1996.
p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells.
Genes Dev.
10:2438-2451[Abstract/Free Full Text].
|
| 7.
|
Chesebro, B.,
K. Wehrly,
M. Cloyd,
W. Britt,
J. Portis,
J. Collins, and J. Nishio.
1981.
Characterization of mouse monoclonal antibodies specific for Friend murine leukemia virus-induced erythroleukemia cells: Friend-specific and FMR-specific antigens.
Virology
112:131-144[Medline].
|
| 8.
|
Deng, C.,
P. Zhang,
J. W. Harper,
S. J. Elledge, and P. Leder.
1995.
Mice lacking p21Cip1/WAF1 undergo normal development, but are defective in G1 checkpoint control.
Cell
82:675-684[Medline].
|
| 9.
|
de Stanchina, E.,
M. E. McCurrach,
F. Zindy,
S.-Y. Shieh,
G. Ferbeyre,
A. V. Samuelson,
C. Prives,
M. F. Roussel,
C. J. Sherr, and S. W. Lowe.
1998.
E1A signaling to p53 involves the p19ARF tumor suppressor.
Genes Dev.
12:2434-2442[Abstract/Free Full Text].
|
| 10.
|
Dulic, V.,
W. K. Kaufmann,
S. J. Wilson,
T. D. Tisty,
E. Lees,
J. W. Harper,
S. J. Elledge, and S. I. Reed.
1994.
p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest.
Cell
76:1013-1023[Medline].
|
| 11.
|
El-Deiry, W. S.,
T. Tokino,
V. E. Velculescu,
D. B. Levy,
R. Parsons,
J. M. Trent,
D. Lin,
W. E. Mercer,
K. W. Kinzler, and B. Vogelstein.
1993.
WAF1, a potential mediator of p53 tumor suppression.
Cell
75:817-825[Medline].
|
| 12.
|
Engelman, A., and N. Rosenberg.
1990.
Temperature-sensitive mutants of Abelson murine leukemia virus deficient in protein tyrosine kinase activity.
J. Virol.
64:4242-4251[Abstract/Free Full Text].
|
| 13.
|
Friedlander, P.,
Y. Haupt,
C. Prives, and M. Oren.
1996.
A mutant p53 that discriminates between p53-responsive genes cannot induce apoptosis.
Mol. Cell. Biol.
16:4961-4971[Abstract].
|
| 14.
|
Green, P. L.,
D. A. Kaehler,
L. M. Bennett, and R. Risser.
1989.
Multiple steps are required for the induction of tumors by Abelson murine leukemia virus.
J. Virol.
63:1989-1994[Abstract/Free Full Text].
|
| 15.
|
Green, P. L.,
D. A. Kaehler, and R. Risser.
1987.
Clonal dominance and progression in Abelson murine leukemia virus lymphomagenesis.
J. Virol.
61:2192-2197[Abstract/Free Full Text].
|
| 16.
|
Harper, J. W.,
G. R. Adami,
N. Wei,
K. Keyomarsi, and S. J. Elledge.
1993.
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1-cyclin-dependent kinases.
Cell
75:805-816[Medline].
|
| 16a.
| Jenab, J., and N. Rosenberg. Unpublished data.
|
| 17.
|
Jones, J. M.,
L. Attardi,
L. A. Godley,
R. Laucirica,
D. Medina,
T. Jacks,
H. E. Varmus, and L. A. Donehower.
1997.
Absence of p53 in a mouse mammary tumor model promotes tumor cell proliferation without affecting apoptosis.
Cell Growth Differ.
8:829-838[Abstract].
|
| 18.
|
Kamijo, T.,
F. Zindy,
M. F. Roussel,
D. E. Quelle,
J. R. Downing,
R. A. Ashmun,
G. Grosveld, and C. J. Sherr.
1997.
Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF.
Cell
91:649-659[Medline].
|
| 19.
|
Kobayashi, T.,
U. Consoli,
M. Audreeff,
H. Shiku,
A. B. Deisseroth, and W. Zhang.
1995.
Activation of p21WAF1/CIP1 expression in a temperature-sensitive mutant of human p53 does not lead to apoptosis.
Oncogene
11:2311-2316[Medline].
|
| 20.
|
Levine, A. J.
1997.
p53, the cellular gatekeeper for growth and division.
Cell
88:323-331[Medline].
|
| 21.
|
McGahon, A. J.,
W. K. Nishioka,
S. J. Martin,
A. Mahboubi,
T. G. Cotter, and D. R. Green.
1995.
Regulation of Fas apoptotic cell death by Abl.
J. Biol. Chem.
270:22625-22631[Abstract/Free Full Text].
|
| 22.
|
Miyashita, T., and J. C. Reed.
1995.
Tumor suppressor p53 is a direct transcriptional activator of the human bax gene.
Cell
80:293-299[Medline].
|
| 23.
|
Mock, B. A.,
E. S. Ramsey, and B. A. Mock.
1998.
Cdkn2, the cyclin-dependent kinase inhibitor encoding p16INK4a and p19ARF, is a candidate for the plasmacytoma susceptibility locus, Pctr.
Proc. Natl. Acad. Sci. USA
95:2429-2434[Abstract/Free Full Text].
|
| 24.
|
Parmar, K.,
R. C. Huebner, and N. Rosenberg.
1991.
Carboxyl-terminal determinants of Abelson protein important for lymphoma induction.
J. Virol.
65:6478-6485[Abstract/Free Full Text].
|
| 25.
|
Parmar, K., and N. Rosenberg.
1996.
Ras complements the carboxyl terminus of v-Abl protein in lymphoid transformation.
J. Virol.
70:1009-1015[Abstract].
|
| 26.
|
Pomerantz, J.,
N. Schreiber-Agus,
N. J. Liegeois,
A. Silverman,
L. Alland,
L. Chin,
J. Potes,
K. Chen,
I. Orlow,
H. W. Lee,
C. Cordon-Cardo, and R. A. DePinho.
1998.
The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53.
Cell
92:713-723[Medline].
|
| 27.
|
Prives, C.
1998.
Signaling to p53: breaking the MDM2-p53 circuit.
Cell
95:5-8[Medline].
|
| 28.
|
Prokocimer, M., and V. Rotter.
1994.
Structure and function of p53 in normal cells and their aberrations in cancer cells: projection on the hematologic cell lineages.
Blood
84:2391-2411[Free Full Text].
|
| 29.
|
Quelle, D. E.,
F. Zindy,
R. A. Ashmun, and C. J. Sherr.
1995.
Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest.
Cell
83:993-1000[Medline].
|
| 30.
|
Radfar, A.,
I. Unnikrishnan,
H.-W. Lee,
R. A. DePinho, and N. Rosenberg.
1998.
P19Arf induces p53-dependent apoptosis during Abelson virus-mediated pre-B cell transformation.
Proc. Natl. Acad. Sci. USA
95:13194-13199[Abstract/Free Full Text].
|
| 31.
|
Reid, S.,
R. Cross, and E. Snow.
1996.
Combined Hoechst 33342 and merocyanin 540 staining to examine murine B cell cycle stage, viability and apoptosis.
J Immunol. Methods
192:43-54[Medline].
|
| 32.
|
Risser, R.,
D. Kaehler, and W. W. Lamph.
1985.
Different genes control the susceptibility of mice to Moloney or Abelson murine leukemia viruses.
J. Virol.
55:547-553[Abstract/Free Full Text].
|
| 33.
|
Risser, R.,
M. Potter, and W. P. Rowe.
1978.
Abelson virus-induced lymphomagenesis in mice.
J. Exp. Med.
148:714-726[Abstract/Free Full Text].
|
| 34.
|
Rosenberg, N.
1991.
abl oncogenes.
Semin. Virol.
2:365-374.
|
| 35.
|
Rosenberg, N., and D. Baltimore.
1976.
A quantitative assay for transformation of bone marrow cells by Abelson murine leukemia virus.
J. Exp. Med.
143:1453-1463[Abstract/Free Full Text].
|
| 36.
|
Ryan, K., and K. Vousden.
1998.
Characterization of structural p53 mutants which show selective defects in apoptosis but no cell cycle arrest.
Mol. Cell. Biol.
18:3692-3698[Abstract/Free Full Text].
|
| 37.
|
Sabbatini, P.,
S.-K. Chiou,
L. Rao, and E. White.
1995.
Modulation of p53-mediated transcriptional repression and apoptosis by adenovirus E1B 19K protein.
Mol. Cell. Biol.
15:1060-1070[Abstract].
|
| 38.
|
Sawyers, C. L.,
W. Callahan, and O. N. Witte.
1992.
Dominant negative myc blocks transformation by abl oncogenes.
Cell
70:901-910[Medline].
|
| 39.
|
Serrano, M.,
A. W. Lin,
M. E. McCurrach,
D. Beach, and S. W. Lowe.
1997.
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a.
Cell
88:593-602[Medline].
|
| 40.
|
Shen, Y. Q., and T. Shenk.
1994.
Relief of p53-mediated transcriptional repression by the adenovirus E1B 19K protein or the cellular bcl-2 protein.
Proc. Natl. Acad. Sci. USA
91:8940-8944[Abstract/Free Full Text].
|
| 41.
|
Sherr, C. J.
1998.
Tumor surveillance via the ARF-p53 pathway.
Genes Dev.
12:2984-2991[Free Full Text].
|
| 42.
|
Shick, L.,
J. H. Carman,
K. Somasundaram,
M. Burrell,
D. E. Hill,
Y.-X. Zeng,
Y. Wang,
K. G. Wiman,
K. Salhany,
T. R. Kadesch,
J. G. Monroe,
L. A. Donehower, and W. S. El-Deiry.
1997.
Decreased immunoglobulin deposition in tumors and increased immature B cells in p53-null mice.
Cell Growth Differ.
8:121-131[Abstract].
|
| 43.
|
Skorski, T.,
M. Nieborowska-Skorska,
P. Wlodarski,
P. Perrotti,
R. Martinez,
M. A. Wasik, and B. Calabretta.
1996.
Blastic transformation of p53-deficient bone marrow cells by P210 bcr/abl tyrosine kinase.
Proc. Natl. Acad. Sci. USA
93:13137-13142[Abstract/Free Full Text].
|
| 44.
|
Stein, D. H., and V. Dulic.
1995.
Origins of G1 arrest in senescent human diploid fibroblasts.
Bioessays
17:537-543[Medline].
|
| 45.
|
Stott, F. J.,
S. Bates,
M. C. James,
B. B. McConnell,
M. Starborg,
S. Brookes,
I. Palmero,
K. Ryan,
E. Hara,
K. H. Vousden, and G. Peters.
1998.
The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2.
EMBO J.
17:5001-5014[Medline].
|
| 46.
|
Stuppia, L.,
G. Calabrese,
R. Peila,
P. Guanciali-Franchi,
E. Morizio,
A. Spadano, and G. Palka.
1997.
p53 loss and point mutations are associated with suppression of apoptosis and progression of CML into myeloid blastic crisis.
Cancer Genet. Cytogenet.
98:28-35[Medline].
|
| 47.
|
Thome, K. C.,
A. Radfar, and N. Rosenberg.
1997.
Mutation of Tp53 contributes to the malignant phenotype of Abelson virus-transformed lymphoid cells.
J. Virol.
71:8149-8156[Abstract].
|
| 48.
|
Votja, P. J., and J. C. Barrett.
1995.
Genetic analysis of cellular senescence.
Biochim. Biophys. Acta
1242:29-41[Medline].
|
| 49.
|
Wagner, A.,
J. M. Kokontis, and N. Hay.
1994.
Myc-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21waf1/cip1.
Genes Dev.
8:2817-2830[Abstract/Free Full Text].
|
| 50.
|
Wang, J. Y. J.
1993.
Abl tyrosine kinase in signal transduction and cell-cycle regulation.
Curr. Opin. Genet. Dev.
3:35-43[Medline].
|
| 51.
|
Whitlock, C. A., and O. N. Witte.
1981.
Abelson virus-infected cells exhibit restricted in vitro growth and low oncogenic potential.
J. Virol.
40:577-584[Abstract/Free Full Text].
|
| 52.
|
Whitlock, C. A.,
S. F. Ziegler, and O. N. Witte.
1983.
Progression of the transformed phenotype in clonal lines of Abelson virus-infected lymphocytes.
Mol. Cell. Biol.
3:596-604[Abstract/Free Full Text].
|
| 53.
|
Wolf, D., and V. Rotter.
1984.
Inactivation of p53 gene expression by an insertion of Moloney murine leukemia virus-like DNA sequences.
Mol. Cell. Biol.
4:1402-1410[Abstract/Free Full Text].
|
| 54.
|
Wong, K. K.,
X. Zou,
K. T. Merrell,
A. J. Patel,
K. B. Marcu,
S. Chellappan, and K. Calame.
1995.
v-Abl activates c-myc transcription through the E2F site.
Mol. Cell. Biol.
15:6535-6544[Abstract].
|
| 55.
|
Xiong, Y.,
G. J. Hannon,
H. Zhang,
D. Casso,
R. Kobayashi, and D. Beach.
1993.
p21 is a universal inhibitor of cyclin kinases.
Nature (London)
366:707-710[Medline].
|
| 56.
|
Zindy, F.,
C. M. Eischen,
D. H. Randle,
T. Kamijo,
J. L. Cleveland,
C. J. Sherr, and M. F. Roussel.
1998.
Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization.
Genes Dev.
12:2424-2433[Abstract/Free Full Text].
|
| 57.
|
Zou, X.,
S. Rudchenko,
K.-K. Wong, and K. Calame.
1997.
Induction of c-myc transcription by the v-Abl tyrosine kinase requires Ras, Raf1, and cyclin-dependent kinases.
Genes Dev.
11:654-662[Abstract/Free Full Text].
|
Molecular and Cellular Biology, July 1999, p. 4825-4831, Vol. 19, No. 7
0270-7306/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Zimmerman, R. S., Rosenberg, N.
(2008). Changes in p19Arf Localization Accompany Apoptotic Crisis during Pre-B-Cell Transformation by Abelson Murine Leukemia Virus. J. Virol.
82: 8383-8391
[Abstract]
[Full Text]
-
Suzuki, J., Shishido, T.
(2007). Regulation of Cellular Transformation by Oncogenic and Normal Abl Kinases. J Biochem
141: 453-458
[Abstract]
[Full Text]
-
Jacobsen, E. A., Ananieva, O., Brown, M. L., Chang, Y.
(2006). Growth, Differentiation, and Malignant Transformation of Pre-B Cells Mediated by Inducible Activation of v-Abl Oncogene.. J. Immunol.
176: 6831-6838
[Abstract]
[Full Text]
-
Nieborowska-Skorska, M., Hoser, G., Rink, L., Malecki, M., Kossev, P., Wasik, M. A., Skorski, T.
(2006). Id1 transcription inhibitor-matrix metalloproteinase 9 axis enhances invasiveness of the breakpoint cluster region/abelson tyrosine kinase-transformed leukemia cells.. Cancer Res.
66: 4108-4116
[Abstract]
[Full Text]
-
Desgranges, Z. P., Ahn, J., Lazebnik, M. B., Ashworth, T., Lee, C., Pestell, R. C., Rosenberg, N., Prives, C., Roy, A. L.
(2005). Inhibition of TFII-I-Dependent Cell Cycle Regulation by p53. Mol. Cell. Biol.
25: 10940-10952
[Abstract]
[Full Text]
-
Marchlik, E., Kalman, R., Rosenberg, N.
(2005). Decreased Virus Population Diversity in p53-Null Mice Infected with Weakly Oncogenic Abelson Virus. J. Virol.
79: 11618-11626
[Abstract]
[Full Text]
-
Sachs, Z., Sharpless, N. E., DePinho, R. A., Rosenberg, N.
(2004). p16Ink4a Interferes with Abelson Virus Transformation by Enhancing Apoptosis. J. Virol.
78: 3304-3311
[Abstract]
[Full Text]
-
Wang, V. E. H., Tantin, D., Chen, J., Sharp, P. A.
(2004). B cell development and immunoglobulin transcription in Oct-1-deficient mice. Proc. Natl. Acad. Sci. USA
101: 2005-2010
[Abstract]
[Full Text]
-
Gong, L., Unnikrishnan, I., Raghavan, A., Parmar, K., Rosenberg, N.
(2004). Active Akt and Functional p53 Modulate Apoptosis in Abelson Virus-Transformed Pre-B Cells. J. Virol.
78: 1636-1644
[Abstract]
[Full Text]
-
Noronha, E. J., Sterling, K. H., Calame, K. L.
(2003). Increased Expression of Bcl-xL and c-Myc Is Associated with Transformation by Abelson Murine Leukemia Virus. J. Biol. Chem.
278: 50915-50922
[Abstract]
[Full Text]
-
Cunningham, L. A., Cote, A. G., Cam-Ozdemir, C., Lewis, S. M.
(2003). Rapid, Stabilizing Palindrome Rearrangements in Somatic Cells by the Center-Break Mechanism. Mol. Cell. Biol.
23: 8740-8750
[Abstract]
[Full Text]
-
Sexl, V., Kovacic, B., Piekorz, R., Moriggl, R., Stoiber, D., Hoffmeyer, A., Liebminger, R., Kudlacek, O., Weisz, E., Rothammer, K., Ihle, J. N.
(2003). Jak1 deficiency leads to enhanced Abelson-induced B-cell tumor formation. Blood
101: 4937-4943
[Abstract]
[Full Text]
-
Unnikrishnan, I., Rosenberg, N.
(2003). Absence of p53 Complements Defects in Abelson Murine Leukemia Virus Signaling. J. Virol.
77: 6208-6215
[Abstract]
[Full Text]
-
Nakamura, Y., Grumont, R. J., Gerondakis, S.
(2002). NF-{kappa}B1 Can Inhibit v-Abl-Induced Lymphoid Transformation by Functioning as a Negative Regulator of Cyclin D1 Expression. Mol. Cell. Biol.
22: 5563-5574
[Abstract]
[Full Text]
-
Ma, P., Magut, M., Chen, X., Chen, C.-Y.
(2002). p53 Is Necessary for the Apoptotic Response Mediated by a Transient Increase of Ras Activity. Mol. Cell. Biol.
22: 2928-2938
[Abstract]
[Full Text]
-
Portis, T., Grossman, W. J., Harding, J. C., Hess, J. L., Ratner, L.
(2001). Analysis of p53 Inactivation in a Human T-Cell Leukemia Virus Type 1 Tax Transgenic Mouse Model. J. Virol.
75: 2185-2193
[Abstract]
[Full Text]
-
Mainville, C. A., Parmar, K., Unnikrishnan, I., Gong, L., Raffel, G. D., Rosenberg, N.
(2001). Temperature-Sensitive Transformation by an Abelson Virus Mutant Encoding an Altered SH2 Domain. J. Virol.
75: 1816-1823
[Abstract]
[Full Text]
-
Jenab-Wolcott, J., Rodriguez-Correa, D., Reitmair, A. H., Mak, T., Rosenberg, N.
(2000). The Absence of Msh2 Alters Abelson Virus Pre-B-Cell Transformation by Influencing p53 Mutation. Mol. Cell. Biol.
20: 8373-8381
[Abstract]
[Full Text]
-
Kabarowski, J. H. S., Witte, O. N.
(2000). Consequences of BCR-ABL Expression within the Hematopoietic Stem Cell in Chronic Myeloid Leukemia. Stem Cells
18: 399-408
[Abstract]
[Full Text]
-
Mostecki, J., Halgren, A., Radfar, A., Sachs, Z., Ravitz, J., Thome, K. C., Rosenberg, N.
(2000). Loss of Heterozygosity at the Ink4a/Arf Locus Facilitates Abelson Virus Transformation of Pre-B Cells. J. Virol.
74: 9479-9487
[Abstract]
[Full Text]
-
Zou, X., Cong, F., Coutts, M., Cattoretti, G., Goff, S. P., Calame, K.
(2000). p53 Deficiency Increases Transformation by v-Abl and Rescues the Ability of a C-Terminally Truncated v-Abl Mutant To Induce Pre-B Lymphoma In Vivo. Mol. Cell. Biol.
20: 628-633
[Abstract]
[Full Text]